− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent since company’s 2018 acquisition − BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco...
Applied Genetic Technologies Corporation has completed enrollment in all dose groups for adult patients with achromatopsia in its phase 1/2 clinical programs, according to a press release. The company is evaluating the safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in...
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious...
VANCOUVER, Washington, March 16, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic...
A quantitative survey conducted by Continuum Clinical late last week indicates as many as one third of clinical research study sites were anticipating significant COVID-19-related interruptions to clinical trial recruitment and retention rates in the weeks and months...
– Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis – Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020...
Email
Text